Sin conexión a internet: se muestra la versión guardada de la página.

Novartis AG ADR

USUSD
← Al screener

Novartis AG ADR (XETRA:NOT) — Drug Manufacturers - General. Número de bolsas en las que cotizan las acciones de la empresa: 7. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.

Sobre la empresa

Sitio web
novartis.com
Sector
Healthcare · Drug Manufacturers - General
Sede central
BASEL, Switzerland
Consejero delegado
Dr. Vasant Narasimhan M.D.
Empleados
75 267
Fundada
1996
Acciones en circulación
1.91 mil M a 2025-12-31
Capital flotante
1.86 mil M
Capitalización bursátil
276.48 mil M USD
Insiders
0.01%
Inversores institucionales
7.27%
Industria (SIC)
Pharmaceutical Preparations
Forma jurídica
MVII
ISIN
CH0012005267
LEI
5493007HIVTX6SY6XD66
Ratio de reparto
56.0%
FCF
17.6 mil M USD
44%
Deuda
29.4 mil M USD
1.0 a. de FCF
Racha de dividendos
20 a.
Beneficios, FCF y dividendos pagados — para los 12 meses hasta 31.12.2025 (el último informe de la compañía).
Descripción

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Bolsas y tickers

BolsaTickerMonedaPrecioTipo
US USA StocksNVSEF OTCUSD135.75 +1.14%acciones ordinarias
LSE London Stock Exchange0QLR IOBCHF82.63 +0.00%acciones ordinarias
MI Borsa Italiana (Milan)1NOVN secundariaEUR127.94 +1.33%acciones ordinarias
SW SIX Swiss ExchangeNOVN principalCHF119.8 -0.13%acciones ordinarias
SW SIX Swiss ExchangeNOVNEE secundariaCHF120.02 -1.80%acciones ordinarias
VI Vienna Stock ExchangeNOVN secundariaEUR127.32 -0.31%acciones ordinarias
XETRA XetraNOT secundariaEUR126.82 +0.48%acciones ordinarias

Precio en 3 meses

día alcista día bajista fecha ex-dividendo fecha de pagoPasa el cursor / toca un día — precios de apertura, cierre, máximo y mínimo

Dividendos

Últimos 12 meses, XETRA:NOT: 3.9091 EUR (1 pagos)

Novartis AG ADR (NOT) paga dividendos una vez al año. En los últimos 12 meses, se pagó 3.9091 EUR por acción (pagos: 1). Eso representa aproximadamente el 3.08% del precio actual de la acción. Según el historial de pagos, se espera la próxima fecha ex-dividendo alrededor de 09.03.2027. Historial de dividendos ininterrumpido: 20 años.

Fecha exPagoImporte%TipoTicker
2026-03-10—3.9091 EUR3.1/3.1 %anualXETRA:NOT
2025-03-11—3.6978 EUR2.9/2.9 %anualXETRA:NOT

Noticias de esta semana

Aún no hay noticias del sitio web de la empresa.

anuncio

Principales accionistas

TitularParticipaciónAccionesFecha del informe
VANGUARD STAR FUNDS-Vang…1.35%27.43 M2026-07-31
VANGUARD TAX-MANAGED FUN…0.9%18.24 M2026-06-30
Fisher Asset Management,…0.76%15.52 M2026-06-30
iShares Trust-iShares Co…0.67%13.69 M2026-08-31
Goldman Sachs TRT II-Gol…0.6%12.19 M2026-07-31
Artisan Partners Funds I…0.51%10.29 M2026-06-30
Dodge & Cox Funds-Dodge…0.44%8.9 M2026-06-30
Morgan Stanley0.43%8.73 M2026-06-30
Dimensional Fund Advisor…0.4%8.12 M2026-06-30
Fidelity Concord Street…0.35%7.12 M2026-07-31
Primecap Management Comp…0.32%6.59 M2026-06-30
iShares Trust-iShares MS…0.32%6.53 M2026-08-31
LOOMIS SAYLES & CO L P0.26%5.24 M2026-06-30
MFS Series Trust XVII-MF…0.26%5.22 M2026-06-30
Bank of America Corporat…0.24%4.91 M2026-06-30
VANGUARD SPECIALIZED FUN…0.23%4.66 M2026-07-31
VANGUARD CHESTER FUNDS-V…0.21%4.25 M2026-06-30
Franklin Resources, Inc.0.16%3.25 M2026-06-30
Blackrock Inc.0.15%3.05 M2026-06-30
Goldman Sachs Group Inc0.15%2.98 M2026-06-30
Northern Trust Corporati…0.14%2.79 M2026-06-30
DFA INVESTMENT DIMENSION…0.11%2.14 M2026-04-30
LOOMIS SAYLES FUNDS II-L…0.07%1.42 M2026-06-30
VANGUARD HORIZON FUNDS-V…0.06%1.21 M2026-06-30
Franklin Mutual Series F…0.06%1.19 M2026-06-30
JANUS INVESTMENT FUND-Ja…0.05%949 7262026-06-30
Principal Funds, Inc-Equ…0.05%945 0912026-04-30
Dimensional ETF Trust-Di…0.04%888 8552026-04-30
Franklin Mutual Series F…0.04%812 6182026-06-30
Dimensional ETF Trust-Di…0.04%716 8362026-04-30
Pacer Advisors, Inc.0.02%482 1532026-06-30
Partners Capital Investm…0%24 3352026-06-30
Paradigm Asset Managemen…0%21 5142026-06-30
Generali Investments Cee…0%15 7292026-06-30